Ferumoxytol-enhanced ultrashort TE MRA and quantitative morphometry of the human kidney vasculature
- 5 March 2021
- journal article
- research article
- Published by Springer Nature in Abdominal Radiology
- Vol. 46 (7) , 3288-3300
Abstract
Purpose To evaluate the feasibility of Quantitative Ultrashort-Time-to-Echo Contrast-Enhanced (QUTE-CE) MRA using ferumoxytol as a contrast agent for abdominal angiography in the kidney. Methods Four subjects underwent ferumoxytol-enhanced MRA with the 3D UTE Spiral VIBE WIP sequence at 3 T. Image quality metrics were quantified, specifically the blood Signal-to-Noise Ratio (SNR), blood-tissue Contrast-to-Noise Ratio (CNR) and Intraluminal Signal Heterogeneity (ISH) from both the aorta and inferior vena cava (IVC). Morphometric analysis of the vessels was performed using manual approach and semi-automatic approach using Vascular Modeling ToolKit (VMTK). Image quality and branching order were compared between QUTE-CE MRA and the Gadolinium (Gd) CEMRA reference image. Results QUTE-CE MRA provides a bright blood snapshot that delineates arteries and veins equally in the same scan. The maximum SNR and CNR values were 3,282 ± 1,218 and 1,295 ± 580, respectively – significantly higher than available literature values using other CEMRA techniques. QUTE-CE MRA had lower ISH and depicted higher vessel branching order (7th vs 3rd) within the kidney compared to a standard dynamic clinical Gd CEMRA scan. Morphometric analysis yielded quantitative results for the total kidney volume, total cyst volume and for diameters of the branching arterial network down to the 7th branch. Vessel curvature was significantly increased (p < 0.001) in the presence of a renal cyst compared to equivalent vessels in normal kidney regions. Conclusion QUTE-CE MRA is feasible for kidney angiography, providing greater detail of kidney vasculature, enabling quantitative morphometric analysis of the abdominal and intra-renal vessels and yielding metrics relevant to vascular diseases while using a contrast agent ferumoxytol that is safe for CKD patients.Keywords
Funding Information
- National Institute on Drug Abuse (1R41DA043974-01)
- National Institute of Diabetes and Digestive and Kidney Diseases (1R21DK118449-01)
This publication has 43 references indexed in Scilit:
- Vascular imaging in chronic kidney diseaseCurrent Opinion in Nephrology and Hypertension, 2012
- Relationship Among Total Kidney Volume, Renal Function and AgeJournal of Urology, 2012
- Renal Arteries: Isotropic, High-Spatial-Resolution, Unenhanced MR Angiography with Three-dimensional Radial Phase ContrastRadiology, 2011
- Biodistribution of gadolinium‐based contrast agents, including gadolinium depositionJournal of Magnetic Resonance Imaging, 2009
- Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?Kidney International, 2009
- Magnetic resonance angiography (MRA) in renally impaired patients: When and howEuropean Journal of Radiology, 2008
- Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequencesPhysics in Medicine & Biology, 2008
- Positive contrast visualization of iron oxide‐labeled stem cells using inversion‐recovery with ON‐resonant water suppression (IRON)Magnetic Resonance in Medicine, 2007
- Accuracy of Computed Tomographic Angiography and Magnetic Resonance Angiography for Diagnosing Renal Artery StenosisPerspectives in Vascular Surgery and Endovascular Therapy, 2005
- Angiogenesis in autosomal-dominant polycystic kidney diseaseKidney International, 2001